Advancing Gene Editing and mRNA Vaccine Technologies in Brazil

March 9, 2022 | 2-5:40 p.m. (BST)


The goal of this program from ASGCT and the Brazilian Association of Cellular and Genetic Therapy (ABTCel-Gen) is for speakers from the U.S. and Brazil to come together and share their expertise on vaccine technology and gene editing. Speakers will discuss the impact of mRNA on the vaccine field and the challenges and successes in manufacturing and viral vector design. The latter half of the event will focus on in vivo and ex vivo gene editing, from basic science through clinical development.

Registered Attendees: Access the Live Event

Agenda

Times are listed in BST. (View this event in your time zone)

Introduction

2-2:10 p.m.

Sang W. Han, PhD, Federal University of Sao Paulo (UNIFESP) 

mRNA Vaccines

2:10-3:10 p.m.  

  • Clinical Experience and Production of mRNA Vaccines
    Patrícia Cristina da Costa Neves, PhD, Biomanguinhos/FIOCRUZ 

  • Developing mRNA Vaccine Technology
    Margaret Liu, MD, ProTherImmune 

  • Panel discussion moderated by Martín Bonamino, PhD, National institute of Cancer (INCA) 

3:10-3:20 p.m.: Break 

In Vivo Gene Editing and Disease Modeling  

3:20-4:20 p.m. 

  • Disease Modeling and Gene Editing in Human iPSC-Derived Cardiomyocytes
    Adriana Bastos Carvalho, PhD, Federal University of Rio de Janeiro (UFRJ) 

  • Liron Walsh, MD, Intellia Therapeutics 

  • Panel discussion moderated by Fernanda Ferreira Cruz, PhD, Federal University of Rio de Janeiro (UFRJ) 

4:20-4:30 p.m.: Break 

Ex Vivo Gene Editing

4:30-5:30 p.m. 

  • Ricardo Weinlich, PhD, Einstein Hospital 

  • Matthew Porteus, MD, PhD, Stanford University School of Medicine

  • Panel discussion moderated by Guilherme Baldo, PhD, Federal University of Rio Grande do Sul (UFRGS)

Closing Remarks

5:30-5:40 p.m.

2022

ASGCT Policy Summit

September 26-27, 2022

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.